Synthego Stock
Genome Engineering Solutions
Sign up today and learn more about Synthego Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Synthego Stock
Synthego is a provider of genome engineering solutions. The company offers CRISPR kits, such as the CRISPR evolution, a portfolio of synthetic RNA designed for CRISPR genome editing and research. Synthego claims that its CRISPR genome engineering technology enables scientists to easily and precisely edit the DNA of any genome. Select applications of gene editing include pathway analysis, stem cells, and diagnostics. The company also offers two products: CRISPR-edited iPS cells and Engineered Cells.
The company is headquartered in Redwood City, CA, and was founded in July 2012. Notable investors include Founders Fund, 8VC, and Menlo Ventures.
Investors
Menlo Ventures
Uber, Chime, Machine Zone, Getaround, BitSight, Recursion Pharmaceuticals, Outreach, Harness, Benchling, Synthego
Founders Fund
Lyft, Spotify, Airbnb, Stripe, Anduril Industries, Flexport, Palantir Technologies, Wish, Compass, Zenefits
8VC
Anduril Industries, Sila Nanotechnologies, Cityblock Health, project44, Blend, Aspiration, Addepar, Illumio, BlueVoyant, Guardant Health
Alexandria Venture
ZhenFund
Bolt Financial, Synthego, The Minerva Project, Artsy, Osaro, Stratifyd
Funding History
June 2013 | $8.3M |
---|---|
December 2016 | $4.4M |
December 2016 | $41.9M |
October 2018 | $116M |
June 2020 | $100M |
December 2021 | $144M |
Management
Chief Executive Officer
Paul Dabrowski
Chief Financial Officer
Avi Raval
Press
patents - Apr, 14 2024
Conjugated crispr-cas complexespatents - Apr, 14 2024
Cell culture laser photoablationpatents - Apr, 14 2024
Systems and Methods for Modulating CRISPR Activitypatents - Apr, 14 2024
Methods and Systems for Guide RNA Design and Usepatents - Apr, 14 2024
Stabilized CRISPR Complexes